期刊文献+

盐酸多奈哌齐治疗轻中度老年痴呆的临床研究 被引量:8

在线阅读 下载PDF
导出
摘要 目的评价盐酸多奈哌齐治疗轻、中度阿尔茨海默病(Alzheimer disease,AD)和血管性痴呆(Vascular dementia,VD)的临床疗效及其药物副作用。方法采用简易智能状态量表(MMSE) 筛选出轻中度AD、VD患者(评分在10-26分之间),并对其进行12周盐酸多奈哌齐治疗,于治疗前,治疗后4、12周末进行Alzheimer病评估量表中文修订版(ADAS-RC)、MMSE、日常生活自理量表(ADL)评定,采用自身对照研究。结果盐酸多奈哌齐治疗4周时,AD组、VD组上述指标已有所改善,治疗12周末较治疗前MMSE、ADAS-RC、ADL分数显著改善,(P<0.01),且AD、VD 两组差异无显著性(P>0.05),52例患者中只有4人出现轻微的副作用。结论盐酸多奈哌齐不仅能改善轻中度AD患者认知功能及日常生活自理能力,对VD也有很好的疗效,而且有较好的耐受性及较高的临床安全性。
出处 《中国老年保健医学》 2006年第2期21-22,共2页 Chinese Journal of Geriatric Care
  • 相关文献

参考文献8

  • 1[1]Rogers SL,Friedhoff LT.Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease:an interim analysis of the results of a US multicentre open label extension study[J].Eur Neuropsychopharmacol.1998,8(1):67-75
  • 2[2]Erkinjuntti T,Roman G,Gauthier S,et al.Energing therapyes for vascular dementia and vascular cognitive impairment[J].Stroke,2004,34(4):1010-1017
  • 3[3]Rogers SL,Farlow MR,Doody RS,et al.A 24-week,double-blind,placebo-controlled trial of donepezil in patients with Alzheimer's disease.Donepezil Study Group[J].Neurology.1998,50(1):136-145
  • 4[4]Mohs RC.The Alzheimer's Disease Assesment Scale[J].Int Psychogeriatr,1996,8(2):195-203
  • 5[5]Farlow M,Potkin S,koumaras B,et al.Analysis of outcome in retrieved dropout patients in a rivastigmine vs planbo,26-week,Alzheimer disease trial[J].Arch Neurol,2003,60(6):843-848
  • 6于欣,王华丽,李淑然,陈玉芳,李海东,贺军.ADAS-Cog中文版区分轻、中度阿尔茨海默病的能力[J].中国心理卫生杂志,2005,19(1):31-33. 被引量:22
  • 7[7]Rogers SL,Friedhoff LT.The efficacy and safety of donepezil in patients with Alzheimer's disease:results of a US Multicentre,Randomized,Double-Blind,Placebo-Controlled Trial.The Donepezil Study Group[J].Dementia.1996,7(6):293-303
  • 8彭丹涛,许贤豪,侯青云,王鲁宁,解恒革,张振馨,王荫华,杨志杰,张新卿,舒良,马辛,金弘敏,蔡琰,吕传真,陈生弟,邵福源,李文贤,俞丽华,高之旭,钱彩韵,王群,徐书雯,潘小平,朱德仪,马崔.安理申治疗轻中度阿尔茨海默病有效性及安全性的临床研究[J].中华神经科杂志,2002,35(1):19-21. 被引量:41

二级参考文献16

  • 1沈渔村,李格,李淑然,陈昌惠,赵友文,刘棉.北京市城区老年期痴呆三年随访研究[J].中国心理卫生杂志,1994,8(4):165-166. 被引量:25
  • 2李格,沈渔邨,陈昌惠,李淑然,张维熙,刘棉.简易精神状态检查表在不同人群中的试测研究[J].中国心理卫生杂志,1989,3(4):148-151. 被引量:98
  • 3Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial.Dement Geriatr Cogn Disord, 1999,10(3):237-44.
  • 4Small G, Erkinjuntti T, Kurz A, et al. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.CNS Drugs, 2003,17(12):905-14.
  • 5Farlow M, Potkin S, Koumaras B, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo,26-week, Alzheimer disease trial. Arch Neurol, 2003,60(6):843-8.
  • 6Doody RS, Geldmacher DS, Gordon B, et al. Open-label,multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol,2001,58(3):427-33.
  • 7McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology,1984.34(7):939-44.
  • 8Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr, 1997,9 Suppl 1:173-6; discussion 177-8.
  • 9Liu HC, Teng EL, Chuang YY, et al. The Alzheimer's Disease Assessment Scale: findings from a low-education population.Dement Geriatr Cogn Disord, 2002,13(1):21-6.
  • 10Wang H, Shu L, Xie J, et al. Diagnostic utility of neuropsychological performance and quantitative MRI-based measurement in Alzheimer's disease. Alzheimer Dis Assoc Disord (in press).

共引文献59

同被引文献63

引证文献8

二级引证文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部